Q3 2024 Devyser Diagnostics AB Earnings Call Transcript
Key Points
- Devyser Diagnostics AB (FRA:OL0) reported strong growth in Europe, with a 27% increase compared to the previous 12 months.
- The company has successfully moved to a new facility, which is expected to drive down production costs and increase gross margins in the future.
- Devyser Diagnostics AB has a strong financial position with 171 million in cash and no interest-bearing debts.
- The collaboration with Thermo Fisher is progressing well, with the largest order ever received from them, indicating strong future potential.
- The company is expanding its presence in North America, with significant investments and a focus on obtaining FDA approval for its products.
- Organic growth was lower than expected, with revenue increasing by only 4% in SEK and 7% in local currency compared to the same quarter last year.
- Gross margins decreased from 85% to 72% due to costs associated with moving to the new facility.
- Sales in North and South America were low compared to last year, indicating challenges in these markets.
- The company's EBIT was negative, amounting to minus 24 million SEK, compared to minus 8 million in the same quarter last year.
- There is uncertainty regarding the timeline for FDA approval, with no specific timeline communicated yet.
Thank you and again, welcome to the device Q3 2024 earnings call. It's a real pleasure to have you all here today. You will listen to me, Fred Als then the device co and T Kipling, our Chief Commercial Officer and responsible for business development.
I have also asked our Co Sabina Bele to join us during the Q&A session.
It's very gratifying to see the impact we are having in the field of diagnostics at the moment.
We have just returned from the ash event, a major transportation conference in the US.
And it's clear that many things are going our way at the moment.
This applies not only to transportation but also to our other areas of operation.
Several milestones were reached during the quarter. We moved all our production and development to our new a proud premises.
A number of product registrations were granted around the world while the development of new products is continuing unbated.
The positive signals, signals that we are seeing mean that we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
